AlphAIAlphAI — Financial news for AI agents
prnewswire.comOCT 242 min read$AMGN

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Amgen (AMGN) announced that IMDELLTRA® combined with AstraZeneca's IMFINZI® reduced the risk of death by 58% in extensive stage small cell lung cancer (ES-SCLC) patients. Median overall survival increased to 21.1 months from 12.7 months with IMFINZI alone. The Phase 3 DeLLphi-305 study results were presented at ESMO Congress 2026 and published in The New England Journal of Medicine.

Original reporting
prnewswire.com
Published Oct 24, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 2:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER — source image
Source · prnewswire.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The trial results could accelerate FDA discussions and boost Amgen’s oncology revenue forecasts.

02

Market read

First‑time disclosure of pivotal trial data likely moves Amgen stock and influences the broader oncology biotech space.

03

What to watch

Regulatory approval timelines and reimbursement uncertainty may temper upside.

Relevance 7/10Novelty 9/10Timing: same‑day release

Background

Amgen’s press release details interim Phase 3 data presented at ESMO 2026, highlighting overall survival and progression‑free survival improvements versus durvalumab alone.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen announced interim Phase 3 DeLLphi-305 results showing a 58% reduction in risk of death for extensive‑stage small cell lung cancer.

Expected impact

likely upside as investors price in the survival benefit

Evidence & confidence

Phase‑3 data are material, first‑time disclosure and directly affect Amgen’s revenue outlook in oncology.

Market effects

Sector

strengthens the biotech oncology sector and may lift peer companies developing SCLC therapies.

Regional

U.S. biotech market may see modest gains; European partners could benefit from trial collaboration.

Global

Adds to global cancer‑treatment pipeline momentum, potentially influencing investor sentiment worldwide.

Counterpoint

What could challenge this read

If long‑term safety concerns emerge, the initial enthusiasm could reverse.

Key entities

  • company
    Amgen

    US‑listed biotech firm reporting the trial data.

  • company
    AstraZeneca

    Partner providing durvalumab in the combination therapy.

Read at source← All news

StoryAmgen’s IMDELLTRA plus AstraZeneca’s IMFINZI cuts death risk by 58% in extensive‑stage small cell lung cancer

Also covered by

2 outlets

Related articles

OCT 24
$AMGNHighAI 9/10

Amgen Announces IMDELLTRA in Combination with Imfinzi Reduces Risk of Death in First-Line Extensive Stage Small Cell Lung Cancer

Amgen reported Phase 3 trial results showing IMDELLTRA with AstraZeneca's IMFINZI reduced death risk by 58% in extensive stage small cell lung cancer. Median progression-free survival was 7.4 months vs. 1.9 months. Safety profiles were consistent with known data. Additional data reinforced sustained outcomes. The trial included 563 patients and was sponsored by Amgen with partial funding from AstraZeneca.

marketscreener.com2 min
OCT 24
$AMGNHighAI 9/10

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced death risk by 58% in extensive-stage small cell lung cancer patients, extending median survival to 21.1 months. The trial suggests potential for Imdelltra's earlier use, boosting its commercial prospects with Q2 sales of $288M, up 115% YoY. Amgen aims to position Imdelltra as a backbone therapy for this aggressive cancer.

cnbc.com2 min
OCT 24
$AMGNHigh

A lung cancer study found nearly 80% of patients alive at one year on two drugs, versus 53% on one.

Amgen's Phase 3 DeLLphi-305 study showed that 80% of patients with extensive-stage small cell lung cancer (ES-SCLC) treated with IMDELLTRA (tarlatamab) and durvalumab survived at one year, compared to 53% with durvalumab alone. The combination therapy also reduced the risk of disease progression or death by 66%. Amgen will discuss these results and its oncology portfolio in an upcoming investor event.

stocktitan.net3 min
OCT 23
$ZYMEHighAI 8/10

Roche Bets $55 Million Upfront on Zymeworks' Trispecific in Bid to Outdo Amgen's Imdelltra — BigGo Finance

Roche will pay Zymeworks $55M upfront for global rights to ZW209, a trispecific T-cell engager targeting small cell lung cancer, with potential total payments of $813M. Zymeworks' shares rose 5.5% premarket. Roche will fund Phase 1a trials, taking over development and commercialization. ZW209 aims to improve on Amgen's Imdelltra, targeting DLL3, CD3, and CD28. The deal is subject to regulatory approvals.

finance.biggo.com2 min